The results of the phase IIa trial found that EP-2104R was able to detect blood clots not previously seen on magnetic resonance imaging (MRI). Blood clots are a major underlying cause of several diseases including deep vein thrombosis, pulmonary embolism, heart attack and stroke.
The data show EP-2104R was well-tolerated and able to detect or enhance clots on MRI images in all six of the body systems studied. In many cases existing modalities are not able to provide a definitive thrombus diagnosis and multiple tests must be conducted to reach a definitive diagnosis.
Epix Pharmaceuticals said it believed EP-2104R could potentially replace multiple tests resulting in significant cost savings.
“EP-2104R detected previously unseen pathologies in some patients in the trial and the results show that we may be able to utilize EP-2104R in contrast enhanced vascular imaging,” said Josef Vymazal, Hospital Na Holmolce, Czech Republic.